Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats

被引：48

作者：

Li, Lei ^{[1
]}

Konishi, Yoshio ^{[2
]}

Morikawa, Takashi ^{[2
]}

Zhang, Yifan ^{[1
]}

Kitabayashi, Chizuko ^{[2
]}

Kobara, Hideki ^{[3
]}

Masaki, Tsutomu ^{[3
]}

Nakano, Daisuke ^{[1
]}

Hitomi, Hirofumi ^{[1
]}

Kobori, Hiroyuki ^{[4
,5
]}

Nishiyama, Akira ^{[1
]}

机构：

[1] Kagawa Univ, Dept Pharmacol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan

[2] Osaka City Gen Hosp, Div Nephrol & Hypertens, Osaka, Japan

[3] Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, Miki, Kagawa, Japan

[4] Int Univ Hlth & Welf, Sch Med, Dept Pharmacol, Tokyo, Japan

[5] Int Univ Hlth & Welf, Sch Med, Dept Nephrol, Tokyo, Japan

来源：

JOURNAL OF PHARMACOLOGICAL SCIENCES | 2018年 / 137卷 / 02期

关键词：

SGLT2; inhibitor; Renineangiotensin system (RAS); Chronic kidney disease (CKD); BLOOD-PRESSURE; EMPAGLIFLOZIN; EFFICACY; SAFETY;

D O I：

10.1016/j.jphs.2017.10.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

We aimed to examine the effects of a sodium glucose co-transporter 2 (SGLT2) inhibitor on systemic and intrarenal renineangiotensin system (RAS) in subtotally nephrectomized non-diabetic rats, a model of chronic kidney disease (CKD). Oral administration of the selective SGLT2 inhibitor, TA-1887 (10 mg/kg/ day), for 10 weeks induced glycosuria. However, plasma renin activity, plasma angiotensinogen levels, kidney angiotensin II contents and renal injury were not significantly affected by TA-1887. These data indicate that chronic treatment with an SGLT2 inhibitor does not activate the systemic and intrarenal RAS in subjects with non-diabetic CKD. (c) 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.

引用

页码：220 / 223

页数：4

共 15 条

[1] Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes [J].

Cherney, David Z. I. ;

Perkins, Bruce A. ;

Soleymanlou, Nima ;

Xiao, Fengxia ;

Zimpelmann, Joseph ;

Woerle, Hans-Juergen ;

Johansen, Odd E. ;

Broedl, Uli C. ;

von Eynatten, Maximilian ;

Burns, Kevin D. .

KIDNEY INTERNATIONAL, 2014, 86 (05) :1057-1058

[2] Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice [J].

Gallo, Linda A. ;

Ward, Micheal S. ;

Fotheringham, Amelia K. ;

Zhuang, Aowen ;

Borg, Danielle J. ;

Flemming, Nicole B. ;

Harvie, Ben M. ;

Kinneally, Toni L. ;

Yeh, Shang-Ming ;

McCarthy, Domenica A. ;

Koepsell, Hermann ;

Vallon, Volker ;

Pollock, Carol ;

Panchapakesan, Usha ;

Forbes, Josephine M. .

SCIENTIFIC REPORTS, 2016, 6

[3] Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus [J].

Haneda, Masakazu ;

Seino, Yutaka ;

Inagaki, Nobuya ;

Kaku, Kohei ;

Sasaki, Takashi ;

Fukatsu, Atsushi ;

Kakiuchi, Haruka ;

Sato, Yuri ;

Sakai, Soichi ;

Samukawa, Yoshishige .

CLINICAL THERAPEUTICS, 2016, 38 (01) :66-88

[4] The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease [J].

Kobori, Hiroyuki ;

Nangaku, Masaomi ;

Navar, L. Gabriel ;

Nishiyama, Akira .

PHARMACOLOGICAL REVIEWS, 2007, 59 (03) :251-287

[5] Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients [J].

Mizushige, Tomoko ;

Kobori, Hiroyuki ;

Hitomi, Hirofumi ;

Nishijima, Yoko ;

Tomoda, Fumihiro ;

Morimoto, Satoshi ;

Kohno, Masakazu ;

Nishiyama, Akira .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (11)

[6] Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents [J].

Oguma, Takahiro ;

Kuriyama, Chiaki ;

Nakayama, Keiko ;

Matsushita, Yasuaki ;

Hikida, Kumiko ;

Tsuda-Tsukimoto, Minoru ;

Saito, Akira ;

Arakawa, Kenji ;

Ueta, Kiichiro ;

Minami, Masabumi ;

Shiotani, Masaharu .

JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 132 (04) :255-261

[7] Angiotensin-Converting Enzyme Inhibitor Does Not Suppress Renal Angiotensin II Levels in Angiotensin I-Infused Rats [J].

Ohnishi, Keisuke ;

Murase, Miki ;

Nakano, Daisuke ;

Pelisch, Nicolas ;

Hitomi, Hirofumi ;

Kobori, Hiroyuki ;

Morimoto, Satoshi ;

Mori, Hirohito ;

Masaki, Tsutomu ;

Ohmori, Koji ;

Kohno, Masakazu ;

Ichihara, Atsuhiro ;

Nishiyama, Akira .

JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 122 (02) :103-108

[8] Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome [J].

Rahman, Asadur ;

Kittikulsuth, Wararat ;

Fujisawa, Yoshihide ;

Sufiun, Abu ;

Rafiq, Kazi ;

Hitomi, Hirofumi ;

Nakano, Daisuke ;

Sohara, Eisei ;

Uchida, Shinichi ;

Nishiyama, Akira .

JOURNAL OF HYPERTENSION, 2016, 34 (05) :893-906

[9] Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes [J].

Shin, Seok Joon ;

Chung, Sungjin ;

Kim, Soo Jung ;

Lee, Eun-Mi ;

Yoo, Young-Hye ;

Kim, Ji-Won ;

Ahn, Yu-Bae ;

Kim, Eun-Sook ;

Moon, Sung-Dae ;

Kim, Myung-Jun ;

Ko, Seung-Hyun .

PLOS ONE, 2016, 11 (11)

[10] A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats [J].

Takeshige, Yui ;

Fujisawa, Yoshihide ;

Rahman, Asadur ;

Kittikulsuth, Wararat ;

Nakano, Daisuke ;

Mori, Hirohito ;

Masaki, Tsutomu ;

Ohmori, Koji ;

Kohno, Masakazu ;

Ogata, Hiroaki ;

Nishiyama, Akira .

HYPERTENSION RESEARCH, 2016, 39 (06) :415-422

← 1 2 →